226. Interstitial cystitis with Hunners ulcer Clinical trials / Disease details
Clinical trials : 145 / Drugs : 156 - (DrugBank : 51) / Drug target genes : 64 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03463499 (ClinicalTrials.gov) | September 22, 2017 | 25/2/2018 | The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients | The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients | Interstitial Cystitis | Drug: Hyaluronic Acid and Chondroitin Sulfate | Samsung Medical Center | NULL | Completed | 20 Years | N/A | All | 62 | N/A | Korea, Republic of |
| 2 | EUCTR2010-021556-25-IT (EUCTR) | 24/02/2011 | 04/11/2010 | Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS)AscoltaTrascrizione foneticaDizionario - Visualizza dizionario dettagliato - IBSA 01-2010 | Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cystitis / painful bladder syndrome (IC / BPS)AscoltaTrascrizione foneticaDizionario - Visualizza dizionario dettagliato - IBSA 01-2010 | Interstitial Cystitis MedDRA version: 9.1;Level: HLGT;Classification code 10018188 | Trade Name: RIMSO 50 INN or Proposed INN: Dimethyl sulfoxide | IBSA | NULL | Not Recruiting | Female: yes Male: no | Phase 3 | Italy | |||
| 3 | NCT00919113 (ClinicalTrials.gov) | July 2009 | 11/6/2009 | Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome | A Multi-Center, Randomized, Double-Blind, Parallel Group Evaluation of the Effectiveness and Safety of Uracyst® Compared to Inactive Control in Subjects With Interstitial Cystitis/Painful Bladder Syndrome | Interstitial Cystitis;Painful Bladder Syndrome | Drug: 2% sodium chondroitin sulfate;Drug: Placebo | Watson Pharmaceuticals | NULL | Completed | 18 Years | N/A | Female | 98 | Phase 2 | United States |